Kinetic Aspects of the Interaction between Ligand and G Protein-Coupled Receptor: The Case of the Adenosine Receptors

被引:49
作者
Guo, Dong [1 ,2 ]
Heitman, Laura H. [1 ]
IJzerman, Adriaan P. [1 ]
机构
[1] Leiden Univ, LACDR, Div Med Chem, POB 9502, NL-2300 RA Leiden, Netherlands
[2] Xuzhou Med Univ, Jiangsu Key Lab New Drug Res & Clin Pharm, 209 Tongshan Rd, Xuzhou 221004, Jiangsu, Peoples R China
关键词
HIGH-AFFINITY ANTAGONIST; TARGET RESIDENCE TIME; AGONIST ALLOSTERIC ENHANCERS; FLUORESCENCE CORRELATION SPECTROSCOPY; SUPERVISED MOLECULAR-DYNAMICS; SITE-DIRECTED MUTAGENESIS; XANTHINE AMINE CONGENER; BIOLOGICAL EVALUATION; A(2A) RECEPTOR; BINDING-KINETICS;
D O I
10.1021/acs.chemrev.6b00025
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Ligand-receptor binding kinetics is an emerging topic in the drug research community. Over the past years, medicinal chemistry approaches from a kinetic perspective have been increasingly applied to G protein-coupled receptors including the adenosine receptors (AR), which are involved in a plethora of physiological and pathological conditions. The study of ligand-AR binding kinetics offers room for detailed structure kinetics relationships next to more traditional structure activity relationships. Their combination may facilitate the triage of candidate compounds in hit-to-lead campaigns. Furthermore, kinetic studies also help in understanding AR allosterism. Allosteric modulation may yield a change in the activity and conformation of a receptor resulting from the binding of a compound at a site distinct from where the endogenous agonist adenosine binds. Hence, in this Review, we summarize available data and evidence for the binding kinetics of orthosteric and allosteric AR ligands. We hope this Review will raise awareness to consider the kinetic aspects of drug target interactions on both ARs and other drug targets.
引用
收藏
页码:38 / 66
页数:29
相关论文
共 238 条
[31]   Adenosine receptors as drug targets - what are the challenges? [J].
Chen, Jiang-Fan ;
Eltzschig, Holger K. ;
Fredholm, Bertil B. .
NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (04) :265-286
[32]   6-aryl-8H-indeno[1,2-d]thiazol-2-ylamines:: A1 adenosine receptor agonist allosteric enhancers having improved potency [J].
Chordia, MD ;
Zigler, M ;
Murphree, LJ ;
Figler, H ;
Macdonald, TL ;
Olsson, RA ;
Linden, J .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (16) :5131-5139
[33]   2-aminothiazoles:: A new class of agonist allosteric enhancers of A1 adenosine receptors [J].
Chordia, MD ;
Murphree, LJ ;
Macdonald, TL ;
Linden, J ;
Olsson, RA .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (12) :1563-1566
[34]   Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery [J].
Christopoulos, A .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (03) :198-210
[35]   International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands [J].
Christopoulos, Arthur ;
Changeux, Jean-Pierre ;
Catterall, William A. ;
Fabbro, Doriano ;
Burris, Thomas P. ;
Cidlowski, John A. ;
Olsen, Richard W. ;
Peters, John A. ;
Neubig, Richard R. ;
Pin, Jean-Philippe ;
Sexton, Patrick M. ;
Kenakin, Terry P. ;
Ehlert, Frederick J. ;
Spedding, Michael ;
Langmead, Christopher J. .
PHARMACOLOGICAL REVIEWS, 2014, 66 (04) :918-947
[36]   Discovery of 1,2,4-Triazine Derivatives as Adenosine A2A Antagonists using Structure Based Drug Design [J].
Congreve, Miles ;
Andrews, Stephen P. ;
Dore, Andrew S. ;
Hollenstein, Kaspar ;
Hurrell, Edward ;
Langmead, Christopher J. ;
Mason, Jonathan S. ;
Ng, Irene W. ;
Tehan, Benjamin ;
Zhukov, Andrei ;
Weir, Malcolm ;
Marshall, Fiona H. .
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (05) :1898-1903
[37]   FRAGMENT SCREENING OF STABILIZED 6-PROTEIN-COUPLED RECEPTORS USING BIOPHYSICAL METHODS [J].
Congreve, Miles ;
Rich, Rebecca L. ;
Myszka, David G. ;
Figaroa, Francis ;
Siegal, Gregg ;
Marshall, Fiona H. .
FRAGMENT-BASED DRUG DESIGN: TOOLS, PRACTICAL APPROACHES, AND EXAMPLES, 2011, 493 :115-136
[38]   Structures of G protein-coupled receptors reveal new opportunities for drug discovery [J].
Cooke, Robert M. ;
Brown, Alastair J. H. ;
Marshall, Fiona H. ;
Mason, Jonathan S. .
DRUG DISCOVERY TODAY, 2015, 20 (11) :1355-1364
[39]   Opinion - Drug-target residence time and its implications for lead optimization [J].
Copeland, Robert A. ;
Pompliano, David L. ;
Meek, Thomas D. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :730-739
[40]   The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety [J].
Copeland, Robert A. .
EXPERT OPINION ON DRUG DISCOVERY, 2010, 5 (04) :305-310